PURPOSE: Recently neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been reported to be inflammatory parameters that confer poorer outcome in metastatic castration-resistant prostate cancer (mCPRPC). However, these ratios have not been analyzed in patients treated with abiraterone acetate. We explored the relationship between different values of PLR and NLR and survival in mCPRCP treated with abiraterone and their possible relation with a prostate specific antigen (PSA) response. METHODS: We retrospectively analyzed 101 patients with mCRPC treated with abiraterone from January of 2012 to November of 2015 in two different hospitals. A cut-off value of 5 for NLR and 150 for PLR were used to compare survival by Kaplan-Meier method. Moreover, an association between these cut-off values and the PSA response was analyzed by a χ 2 test. RESULTS: In the case of NLR, the median DFS were 12, 1 months for NLR <5 and 7 months for NLR ≥5, p = 0.061. The median OS were 23.9 months for NLR <5 and 16.3 months for NLR ≥5, p = 0.046. In the case of PLR, the median DFS were 11.8 months for PLR <150 and 10.6 months for PLR ≥150, p = 0.549. The median OS were 27.4 months for PLR <150 and 15.9 months for PLR ≥150, p = 0.005. It was not observed a correlation between the different cut-off values of PLR or NLR and a PSA response ≥25% (p = 0.31). CONCLUSIONS: It is shown a better prognostic relationship between PLR and NLR low values and OS that is statistically significant in mCPRC patients treated with abiraterone. Furthermore, it was not shown a relation between PLR and NLR values and PSA response.
PURPOSE: Recently neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been reported to be inflammatory parameters that confer poorer outcome in metastatic castration-resistant prostate cancer (mCPRPC). However, these ratios have not been analyzed in patients treated with abiraterone acetate. We explored the relationship between different values of PLR and NLR and survival in mCPRCP treated with abiraterone and their possible relation with a prostate specific antigen (PSA) response. METHODS: We retrospectively analyzed 101 patients with mCRPC treated with abiraterone from January of 2012 to November of 2015 in two different hospitals. A cut-off value of 5 for NLR and 150 for PLR were used to compare survival by Kaplan-Meier method. Moreover, an association between these cut-off values and the PSA response was analyzed by a χ 2 test. RESULTS: In the case of NLR, the median DFS were 12, 1 months for NLR <5 and 7 months for NLR ≥5, p = 0.061. The median OS were 23.9 months for NLR <5 and 16.3 months for NLR ≥5, p = 0.046. In the case of PLR, the median DFS were 11.8 months for PLR <150 and 10.6 months for PLR ≥150, p = 0.549. The median OS were 27.4 months for PLR <150 and 15.9 months for PLR ≥150, p = 0.005. It was not observed a correlation between the different cut-off values of PLR or NLR and a PSA response ≥25% (p = 0.31). CONCLUSIONS: It is shown a better prognostic relationship between PLR and NLR low values and OS that is statistically significant in mCPRC patients treated with abiraterone. Furthermore, it was not shown a relation between PLR and NLR values and PSA response.
Authors: Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan Journal: Med Oncol Date: 2014-09-14 Impact factor: 3.064
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Kultigin Turkmen; Fatih Mehmet Erdur; Fatih Ozcicek; Adalet Ozcicek; Emin Murat Akbas; Aysu Ozbicer; Levent Demirtas; Suleyman Turk; H Zeki Tonbul Journal: Hemodial Int Date: 2013-03-24 Impact factor: 1.812
Authors: Arnoud J Templeton; Carmel Pezaro; Aurelius Omlin; Mairéad G McNamara; Raya Leibowitz-Amit; Francisco E Vera-Badillo; Gerhardt Attard; Johann S de Bono; Ian F Tannock; Eitan Amir Journal: Cancer Date: 2014-07-03 Impact factor: 6.860
Authors: Matteo Ferro; Ottavio De Cobelli; Carlo Buonerba; Giuseppe Di Lorenzo; Marco Capece; Dario Bruzzese; Riccardo Autorino; Danilo Bottero; Antonio Cioffi; Deliu Victor Matei; Michele Caraglia; Marco Borghesi; Ettore De Berardinis; Gian Maria Busetto; Riccardo Giovannone; Giuseppe Lucarelli; Pasquale Ditonno; Sisto Perdonà; Pierluigi Bove; Luigi Castaldo; Rodolfo Hurle; Gennaro Musi; Antonio Brescia; Michele Olivieri; Amelia Cimmino; Vincenzo Altieri; Rocco Damiano; Francesco Cantiello; Vincenzo Serretta; Sabino De Placido; Vincenzo Mirone; Guru Sonpavde; Daniela Terracciano Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817
Authors: Oliver E Yausep; Raksheeth Agarwal; Rifqha Aulina; Anthony E Wijaya; Ilonka Amaia; Addina W Moekti; Ikhwan Rinaldi; Agus Rizal A H Hamid Journal: Clin Case Rep Date: 2019-07-11